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Abstract: Pompe disease is a lysosomal storage disorder characterized by muscle weakness 
and cardiomyopathy. It shows a broad variability regarding the clinical severity as well as the 
age of onset. In the past, two different recombinant enzyme preparations have been developed 
for the treatment of Pompe patients: α-glucosidase, produced in rabbit milk, and α-glucosidase, 
produced in Chinese hamster ovary (CHO) cell lines. The CHO enzyme received marketing 
approval in 2006 after it was proven to be effective in ameliorating muscle strength and improving 
heart function. The other has not been approved. The clinical efficacy of this enzyme preparation 
could be confirmed by several clinical trials in patients with different age of onset and disease 
severity. Enzyme replacement therapy, however, has its limitations due to unsatisfactory access 
of recombinant α-glucosidase to the muscle cells and due to the formation of antibodies. 
To overcome these therapeutic restraints, the development of a more effective enzyme preparation 
may become necessary.
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Introduction
Pompe disease, also known as glycogenosis type II or acid maltase deficiency, is 
a lysosomal storage disorder that is caused by the genetic defect of the enzyme 
α-glucosidase. Deficient activity of this enzyme results in glycogen accumulation 
in several tissues leading to progressive cardiomyopathy, skeletal muscle weakness, 
and respiratory insufficiency.1 Umapathysivam and colleagues demonstrated that 
α-glucosidase activity and glycogen concentration in skin fibroblasts is clearly 
correlated with age of onset.2 A profound deficiency or even absence of α-glucosidase 
activity leads to a rapid accumulation in skeletal and heart muscle, resulting in the 
infantile (early-onset) form of Pompe disease that is characterized by severe muscle 
weakness, hypertrophic cardiomyopathy, and early death. Patients with a higher residual 
enzyme activity experience a slower progression of the disease, leading to the juvenile 
type where muscular weakness and respiratory insufficiency are the leading symptoms. 
The occurrence of hearing loss has been observed in young children with Pompe 
disease.3 In the adult form, the first symptoms such as slow, progressive myopathy, 
mainly in the muscles of the hip, thigh, and spine, and respiratory insufficiency begin 
at the third decade. The development of spine deformities is very common. In later life, 
many patients become wheelchair-bound and require artificial ventilation.4 In the late-
onset form heart involvement is not as frequent as in early-onset phenotypes. In adults, 
accumulation of glycogen in vascular smooth-muscle may result in intracranial Therapeutics and Clinical Risk Management 2009:5 768
Beck Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
aneurysm or arteriopathy, leading to multiple intracerebral 
embolisms and hemorrhage.5
Pompe disease is inherited in an autosomal-recessive 
manner. The gene encoding acid α-glucosidase is localized 
on chromosome 17q25 and contains 19 exons. In 2008, 289 
sequence variations, 67 nonpathogenetic mutations and 197 
pathogenetic mutations have been listed in the Pompe disease 
mutation database.6 The most common mutations in the 
Dutch population are IVS1 (-13T  G), c.del525, and del 
exon 18.7 The incidenc of Pompe disease varies in different 
ethnic groups between 1:40,000 and 1:50,000.7
In the past, no specific therapy was available for patients 
affected by Pompe disease, and management consisted solely 
of treatment of complications and supportive care such as 
nutrition and exercise therapy.8
Development of enzyme 
preparations
Since enzyme replacement therapy has been successfully 
introduced for patients with Gaucher disease, this principle 
of treatment has been developed for other lysosomal storage 
disorders such as mucopolysaccharidose types I, II, and VI and 
Fabry disease. Decades ago it was recognized that various cell 
types need specific receptors for uptake of exogenous lyso-
somal enzymes.9 The hepatocyte membrane contains galactose 
receptors, macrophages require mannose residues for uptake, 
whereas most cells bind exogenous enzymes via the mannose-
6-phosphate (M6P) receptor. This fact explains why the initial 
trials of enzyme replacement therapy in an α-glucosidase 
deficient mouse (mouse model for Pompe disease) failed. In 
these early experiments, a nonphosphorylated human placenta 
α-glucosidase was used and was shown not to be taken up by 
the heart and skeletal muscle. Later studies have demonstrated 
that an enzyme preparation isolated from bovine testes that 
contained M6P was much more efficient in correcting the 
biochemical defect in affected tissues.10
Two different forms of human α-glucosidase that con-
tain M6P have been developed by recombinant techniques: 
Enzyme produced either in Chinese hamster ovary (CHO) 
cell lines or in milk of transgenic rabbits. The biochemical 
and pharmacological properties of both enzyme preparations 
have been analyzed by McVie-Wylie and colleagues.11 They 
found that in both enzyme preparations the predominant 
species was the precursor (110 kDa) form of the molecule 
that contains M6P in a molar ratio of about 1.2–1.3, whereas 
human placenta contains mainly the processed 76 kDa form 
that lacks this essential targeting signal and therefore is 
not effectively taken up by human fibroblasts. Analysis of 
receptor binding and cell uptake, performed in fibroblasts 
from patients affected by Pompe disease, demonstrated that 
the uptake of α-glucosidase produced in CHO cells was 
higher than that of the rabbit milk enzyme. Clearance of 
muscle glycogen was measured in α-glucosidase knockout 
mice administered either CHO or rabbit milk α-glucosidase. 
Both enzyme preparations resulted in a reduction of tissue 
glycogen content in a dose-dependent manner, although 
higher levels of enzyme activity were detected in the muscle 
of mice who received the rabbit milk enzyme when compared 
to those treated with the CHO enzyme. This discrepancy can 
be explained by unproductive uptake of enzyme by resident 
endothelial and fibroblasts rather than by glycogen-containing 
myocytes. Both the milk enzyme and the CHO cell-derived 
enzyme were used in clinical trials. Taking into account the 
limited life expectancy of the disease following diagnosis, 
a placebo control was included in none of these studies.
Rabbit milk α-glucosidase
The first clinical trial with recombinant human α-glucosidase 
from transgenic rabbit milk started in 1999.12 Four patients with 
the infantile form of Pompe disease received the enzyme once 
a week at dosages increasing from 15 mg/kg to 40 mg/kg. After 
36 weeks of treatment, left ventricular mass index decreased 
significantly, skeletal muscle morphology and motor function 
improved. In another trial, four Pompe patients (2.5–8 months 
of age) were enrolled in a single-center open-label study and 
treated for at least three years with recombinant α-glucosidase 
that was purified from the milk of transgenic rabbits. At the 
beginning of the study a dose of 15 to 20 mg/kg/week was 
used, and at week 12 the dose was increased to 40 mg/kg/week. 
The treatment resulted in a dramatic decrease in heart size and 
improvement of heart function. Signs of regeneration were 
found in muscle biopsies. All patients survived beyond the age 
of four years, but one died at the age of four years and three 
months after a short period of intractable fever. Two infants 
became ventilator-dependent.13
The efficacy of α-glucosidase produced in the milk of 
transgenic rabbits was also studied in three patients aged 
11, 16, and 32 years with late-onset Pompe’s disease.14 In all 
patients, weekly infusions of this enzyme led to stabilization 
of lung function and even improvement of skeletal muscle 
strength in one child.
CHO α-glucosidase
Clinical trials
Three infants were included in the first human study with 
recombinant enzyme from CHO cell lines.15 Based on the Therapeutics and Clinical Risk Management 2009:5 769
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fact that virtually all patients with Pompe disease die before 
one year of age, the heart failure-free survival at one year 
of age was defined as the primary end point. In this trial, 
patients received the recombinant enzyme twice weekly. The 
infusions were generally well tolerated. All infants survived 
the first year of life with well preserved heart function. 
Muscle strength also improved and a reduction of glycogen 
accumulation was seen in muscle biopsies.
In an open-label, multinational, multicenter clinical 
trial, eight infantile Pompe patients were enrolled.16 After 
52 weeks of treatment with recombinant α-glucosidase at 
a weekly dosage of 10 mg/kg, six of the eight were alive, 
and five patients were free of invasive ventilator support. 
Furthermore, an improvement of heart function was observed, 
and five patients achieved new motor milestones.
Kishnani and colleagues examined the efficacy and safety 
of recombinant α-glucosidase produced in CHO cells in a 
large number of severely affected Pompe patients.17 The 
study was designed to demonstrate a positive effect on 
survival compared to a historical control population. This 
control group consisted of 61 severely affected infants six 
months old or younger, who were included in a retrospective 
natural history study.18 The patients, who were no older than 
26 weeks at initiation of the study, received intravenous 
infusions of the enzyme preparation at 20 mg/kg (n = 9) or 
40 mg/kg (n = 9) every other week. All 18 patients survived to 
18 months of age. A statistical analysis performed 52 weeks 
after the last patient was randomized to the study revealed 
that treatment with α-glucosidase reduced the risk of death 
or invasive ventilation by 92% compared to the untreated 
historical control group. After the end of the study, mean 
left ventricular mass index had declined from 193.4 g/m2 at 
baseline to 86.8 g/m2. Consistent motor and functional gains 
were observed in 13 of 18 patients measured by the Alberta 
Infant Motor Scale. During the study, all patients acquired 
cognitive and social development skills, although generally 
not as fast as healthy infants of the same age.
In all patients a muscle biopsy was performed at baseline 
and weeks 12 and 52 in order to assay α-glucosidase activity 
and glycogen levels. In both dosage groups, a significant 
increase in muscle enzyme activity from baseline to week 52 
could be demonstrated. Fifteen of the 17 patients in whom 
levels of storage material had been measured exhibited stable 
or decreased muscle glycogen content (20% depletion) at the 
end of the trial as compared to baseline. The 40 mg/kg dose was 
not superior to the 20 mg/kg dose with regard to efficacy.
In an extension study, 16 of the 18 patients of the 52-week 
trial continued to receive α-glucosidase at the same dose 
to which they were originally assigned.19 At the age of 
24 and 36 months, survival and ventilator use (invasive and 
noninvasive) were analyzed. At 36 months, the survival rate 
was 72%, whereas only one of 61 patients in the untreated 
control group survived to the ages of 24 and 36 months. 
The invasive ventilation-free survival rate, evaluated as 
the primary efficacy endpoint, was 66.7% at the age of 24 
months and 49.4% at age of 36 months. In contrast, the overall 
survival rate of untreated patients is much lower.
As a secondary endpoint the proportion of patients who 
were alive and free from any ventilatory support (invasive 
or noninvasive) was chosen. As no additional infants 
needed noninvasive ventilatory support at the ages of 24 or 
36 months, the ventilation-free survival rate was the same as 
the invasive ventilation-free survival rate, namely 66.7% and 
49.4%, respectively. Cardiac parameters and motor develop-
ment were evaluated as in the foregoing 52-week trial: During 
the extension study mean left ventricular mass continued to 
decrease and remained stable at the end of the trial. Seven 
infants gained motor skills and became able to walk at the 
time of their final assessment. The study was terminated 
after the enzyme preparation alglucosidase alfa (Myozyme®; 
Genzyme, Cambridge, MA, USA), manufactured in a CHO 
cell line, was approved for commercial use in 2006.
In order to evaluate whether enzyme replacement therapy 
with alglucosidase alfa was safe and effective in children 
with advanced Pompe disease, an open-label, multicenter 
study was initiated that included 21 infants who were aged 
3–43 months at enrollment.20 All patients received a dosage of 
20 mg/kg every two weeks initially and after at least 26 weeks 
of treatment, an increase of dosage to 40 mg/kg every two 
weeks was allowed if the patient’s clinical condition relative to 
baseline had significantly deteriorated. To compare survival 
results, the same untreated patients served as a reference 
cohort that was also used in the first 52-week study.18 Data 
analysis at the end of the study revealed that treatment with 
alglucosidase alfa reduced the risk of death by 79% and 
the risk of invasive ventilation by 58% compared with the 
untreated historical group. Echocardiography demonstrated 
that left ventricular mass index improved or remained normal 
in all patients evaluated beyond 12 weeks. Thirteen of the 
21 patients achieved new motor milestones and five patients 
were able to walk independently at the end of the study
The effect of enzyme replacement therapy in late-
onset Pompe disease has been investigated in 44 patients 
with various stages of disease.21 Mean age at baseline was 
48.9 years and the age range was 21 to 69 years. Standard 
dosage was 20 mg/kg alglucosidase alfa every other week. Therapeutics and Clinical Risk Management 2009:5 770
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After one year of treatment, a significant improvement of 
the six-minute walk test could be seen (from 341 ± 149 m at 
baseline to 393 ± 157 m after one year of treatment). Creatine 
kinase serum levels showed a significant mean decrease of 
10.5%. Lung function remained unchanged.
Safety
In the studies performed by Kishnani and colleagues,17,19 
16 of the 18 patients developed immunoglobulin G (IgG) 
antibodies to glucosidase alfa at different times of the study. 
Eleven of the 18 patients experienced 224 mild or moderate 
infusion-associated reactions that were defined as drug-related 
adverse events. More infusion-associated reactions occurred 
in patients who received the high dosage (40 mg/kg) than in 
patients in the 20 mg/kg dose group. Rash, fever, urticaria, 
and decreased oxygen saturation were the most common 
infusion-associated reactions. They could be managed easily 
by stopping the infusion or reducing the infusion rate. All 
patients who experienced infusion-associated reaction recov-
ered without any sequelae, and no patient had to discontinue 
treatment because of an adverse event.
Limitations of enzyme  
replacement therapy
Clearance of glycogen from the skeletal muscle of Pompe 
patients has been shown to be more difficult than substrate 
elimination in other lysosomal storage disorders, and several 
factors contribute to the limited efficay of enzyme replace-
ment therapy in Pompe disease. At first, muscle cells are 
separated from the bloodstream by a barrier composed of 
endothelial cells and ample interstitial tissue, whereas in 
Fabry and Gaucher disease, the target cells (endothelial 
cells and macrophages, respectively) are located close to 
the blood vessels from where they take up immediately the 
administered enzyme. Furthermore, muscle and heart differ 
in the response to exogenously administered enzyme due 
to diversity in the density of the M6P receptor in different 
tissues. It has been shown that the skeletal muscle contains 
much less M6P receptors than heart cells.22 Therefore very 
high amounts of enzyme (up to 40 mg/kg body weight) are 
necessary to achieve a therapeutic effect not only in cardiac 
tissue, but also in skeletal muscle. In addition, type II muscle 
fibers are more resistant to glycogen clearance than type I 
fibers, most likely because type II fibers contain less proteins 
involved in endocytosis and trafficking of lysosomal enzymes 
and do show an increased autophagic activity.23 One of the 
greatest barriers to successful enzyme replacement therapy 
in Pompe disease is the fact that the efficacy is markedly 
reduced by the formation of high-titer antibodies against 
human α-glucosidase in subjects who are negative for 
cross-reacting immunologic material (CRIM).17 It can be 
shown in a mouse model of Pompe disease that the forma-
tion of antibodies can be prevented by adeno-associated virus 
vector-mediated gene therapy that induced immune tolerance 
to the infused enzyme.24
Some limitations of enzyme replacement therapy in 
Pompe disease are possibly due to the timing of therapy 
and early therapeutic intervention has been shown be 
more efficient. Therefore, newborn screening programs for 
lysosomal storage disorder have been developed.25 However, 
as for most of these conditions a strict genotype–phenotype 
correlation does not exist, the screening programs will 
probably not be generally introduced until the phenotype 
from the newborn result can be exactly predicted.
Perspectives of future therapies
Modification of α-glucosidase
As it has been discussed before, the delivery of alglucosidase 
alfa to the target cells depends from the number of M6P 
residues the enzyme contains. And in order to increase 
the density of the recognition marker Zhu and colleagues 
have modified the enzyme by conjugation of a synthetic 
oligosaccharide containing M6P residues onto recombinant 
human acid α-glucosidase.26 This modification improved the 
affinity of the enzyme for the M6P receptor and delivery to 
the muscle cells. Infusion of the M6P-enriched enzyme into 
Pompe mice resulted in a significantly higher clearance of 
glycogen in muscle cells when compared to the unmodified 
counterpart. A greater improvement in muscle strength was 
observed. It can be assumed that the modified enzyme may 
be more effective in the treatment of Pompe patients.
Chaperones
Chaperones are a part of the cell system that has the task 
to control the quality of newly synthesized proteins by 
eliminating misfolded or unstable mutant products. Besides 
the chaperones this machinery involves proteosomes and the 
ubiquitin system. And in the last years it has been found that 
iminosugars do not only act as enzyme inhibitors, but also 
have an effect as pharmacological chaperones.27 In genetic 
disorders, certain missense mutations and some small in-frame 
deletions may cause polypeptide misfolding, but may not 
(or only slightly) impair the functionally essential domains of 
the mutant protein (the active site, receptor-binding site, etc). 
Pharmacological chaperones, such as substrate analogues, 
may facilitate the stabilization of misfolded proteins and Therapeutics and Clinical Risk Management 2009:5 771
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iminosugars such as deoxynojirimycin-analogues function 
as chaperones.
In summary, small molecule chemical chaperones may 
be therapeutically useful for various lysosomal storage 
disorders caused by mutant but yet catalytically active 
enzymes. Porto and colleagues studied the combined effect 
of recombinant α-glucosidase and the pharmacological 
chaperone N-butyldeoxynojirimycin (NB-DNJ) on the 
efficacy of enzyme activity in cultured Pompe fibroblasts 
and showed that the chaperone improved enzyme delivery 
to lysosomes, enhanced enzyme maturation, and increased 
enzyme stability.28 A similar effect on α-glucosidase activity 
was also oberved in a mouse model of Pompe disease that, 
in addition to a single infusion of recombinant human 
α-glcucosidase, was treated with oral NB-DNJ.
Conclusion
In summarizing the results of the different clinical trials 
with recombinant α-glucosidase, it can be concluded that 
treatment with this enzyme preparation is able to improve 
cardiomyopathy and motor development. The current 
enzyme replacement therapy improves quality of life of 
the patients, but does not cure them. The effect on muscle 
function is not as satisfactory as to that on the heart because 
of the variability of skeletal muscle response. In addition, 
the efficacy of enzyme replacement therapy is reduced by 
the formation of antibodies, predominantly in CRIM-nega-
tive patients. It has also become evident that the outcome 
is more robust if treatment starts in early life, for which 
reason several screening programs for Pompe disease will be 
initiated. In order to overcome these limitations of enzyme-
replacement therapy in Pompe disease, many efforts have 
to be made to modify recombinant α-glucosidase to have 
better access to muscle cells, to prevent antibody formation, 
and to develop new drugs such as chaperones that may 
increase enzyme activity. In the future, gene therapy may 
be a therapeutic option.29
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